Discussion: some comments on the potential carcinogenicity of the clinically useful antitumor agents.
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002273:Carcinogens; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced; D004052:Diethylnitrosamine / Q000008:administration & dosage; D000882:Haplorhini; D006801:Humans; D008113:Liver Neoplasms / Q000139:chemically induced; D008770:Methylnitrosourea / Q000009:adverse effects; D009374:Neoplasms, Experimental / Q000139:chemically induced*; D009378:Neoplasms, Multiple Primary / Q000209:etiology; D011344:Procarbazine / Q000009:adverse effects; D012042:Registries
D000970:Antineoplastic Agents; D002273:Carcinogens; D011344:Procarbazine; D004052:Diethylnitrosamine; D008770:Methylnitrosourea